| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
9,273 |
7,727 |
$430K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
5,731 |
4,869 |
$397K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
2,036 |
1,707 |
$151K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
2,526 |
2,211 |
$102K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
2,212 |
1,908 |
$51K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,987 |
1,733 |
$49K |
| 87631 |
|
336 |
317 |
$34K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
82 |
82 |
$30K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
285 |
271 |
$24K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
49 |
45 |
$17K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
331 |
319 |
$16K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
161 |
147 |
$12K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
142 |
135 |
$12K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
120 |
114 |
$10K |
| 90756 |
|
211 |
157 |
$5K |
| 82962 |
|
2,127 |
1,747 |
$4K |
| 87641 |
|
53 |
49 |
$2K |
| 87486 |
|
53 |
49 |
$2K |
| 87581 |
|
53 |
49 |
$2K |
| 90661 |
|
74 |
62 |
$2K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
68 |
64 |
$2K |
| 87529 |
|
13 |
13 |
$904.78 |
| 36415 |
Collection of venous blood by venipuncture |
178 |
164 |
$480.35 |
| 90686 |
|
50 |
46 |
$454.76 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
13 |
13 |
$452.37 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
13 |
13 |
$452.37 |
| 86580 |
|
110 |
102 |
$440.00 |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
13 |
13 |
$370.24 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
32 |
28 |
$358.90 |
| 90674 |
|
16 |
16 |
$298.50 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
16 |
16 |
$251.20 |
| 90619 |
|
13 |
13 |
$217.23 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
381 |
322 |
$213.70 |
| 99406 |
|
19 |
14 |
$127.50 |
| 90734 |
|
15 |
13 |
$96.00 |